Factors affecting outcome of longer regimen multidrug-resistant tuberculosis treatment in
West Java Indonesia: A retrospective cohort study

Arto Yuwono Soeroto, Chica Pratiwi, Prayudi Santoso, Bony Wiem Lestari

1 Division of Respirology and Critical Care Medicine, Department of Internal Medicine, Faculty of Medicine
Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital, Bandung, West Java, Indonesia,
2 Department of Internal Medicine, Faculty of Medicine Universitas Padjadjaran, Dr. Hasan Sadikin General Hospital,
Bandung, West Java, Indonesia,
3 Department of Public Health, Faculty of Medicine Universitas
Padjadjaran, Bandung, West Java, Indonesia,
4 TB-HIV Research Center, Faculty of Medicine Universitas
Padjadjaran, Bandung, West Java, Indonesia.

These authors contributed equally to this work.

* aysoeroto@yahoo.co.id

Abstract

Background

Multidrug-resistant tuberculosis had high treatment failure and mortality. Success rate of
treatment currently 56% at global level, 48% in Indonesia and 36% in West Java province,
the most populated province and surround Jakarta, the capitol of Indonesia.

Objective

This study aimed to evaluate factors affecting success of multidrug-resistant tuberculosis
treatment in patients using longer treatment regimen in West Java Indonesia.

Methods

This was a retrospective cohort study of multidrug-resistant tuberculosis patients treated
with longer regimen at Hasan Sadikin General Hospital from January 2015 to December
2017. Potential risk factors associated with the treatment outcome were analyzed using mul-
tiple logistic regression.

Results

A total of 492 patients were enrolled during the study period. Fifty percents multidrug-resis-
tant tuberculosis patients had successful treatment outcome. Age ≤45 years, male, normal
body mass index, no previous tuberculosis treatment, culture conversion ≤2 months, acid
fast bacilli sputum smear ≤+1 were independent factors associated with increased treatment
success. Sputum culture conversion ≤2 months was the major factor affecting suc-
cessful outcome (RR 2.79; 95% CI: 1.61–4.84; p-value<0.001).

Human Immunodeficiency
Virus infection, chronic kidney disease, and cavitary lesion were independent risk factors for unfavourable outcome.

**Conclusion**

Age, gender, body mass index, tuberculosis treatment history, time of sputum conversion, acid fast bacilli sputum smear, HIV infection, chronic kidney disease, and cavitary lesion can be used as predictors for longer multidrug-resistant tuberculosis treatment regimen outcome.

**Introduction**

Multidrug-resistant tuberculosis (MDR-TB) is a condition in which *Mycobacterium tuberculosis* is resistant to at least isoniazid and rifampicin. MDR-TB cases is increasing every year globally. There were 160,684 new cases of MDR-TB in 2017 and 186,772 new cases in 2018. MDR-TB was detected in 3.4% of new TB cases and 18% of previously treated cases [1]. The burden of MDR-TB varies among countries where India (27%), China (14%), and The Russian Federation (9%) were the top three countries contributed to the largest share of the global burden [1]. MDR-TB was also a growing problem in low incidence countries. TB surveillance in the European Union or European Economic Area (EU/EEA) countries in 2014 showed that 4.0% of TB cases were MDR-TB (2.2% of all notified TB cases) as identified by the drug susceptibility testing (DST) [2]. While the prevalence of MDR-TB from TB cases undergoing DST was 1.2% in the US, 1.3% in Canada, and 2% in Australia [2].

Indonesia is one of 20 main countries with the highest burden of MDR-TB. WHO (World Health Organization) estimates in 2018, cases of MDR-TB in Indonesia were about 24,000 cases per year including 2.4% of new TB (Tuberculosis) cases and 13% of re-treatment TB cases with treatment success rate of 48% [1]. West Java is one of provinces in Indonesia with most of MDR-TB cases. Based on Ministry of Health data, there were 1,566 new cases in 2018 and 2,073 cases in 2019. There only 45–50% MDR-TB cases that got treated, with 36% success rate in West Java [3]. A study in West Java showed that living in rural area was associated with delay to MDR-TB diagnosis and treatment initiation, with median time to diagnosis was 14 days and 25 days for treatment [4]. However, no study has been performed in Indonesia to evaluate risk factors associated with MDR-TB treatment outcome, especially in West Java.

MDR-TB has a high treatment failure rate and death. In 2018, WHO data showed that of those with MDR-TB in the world, only 32% of cases underwent therapy, with a success rate of 56%. Researches conducted in countries with a high burden of MDR-TB found different factors that affect MDR-TB treatment outcomes. In China, MDR-TB patients who smoke, drink, have ofloxacin resistance, or a high smear grade are less likely to respond to treatment. Predictors of unsuccessful treatment in Egypt were delayed culture conversion, moderate or extensive lung affection, and diabetes mellitus. India found different factors affected poor treatment outcome like baseline BMI < 18, seven missed doses in intensive phase and continuation phase, cavitary disease, prior treatment episodes, longer duration and more episodes of treatment, any weight loss during treatment, males and additional resistance to first line drugs (Ethambutol, Streptomycin) [5–7]. Some socioeconomic determinants had also been associated with failure of MDR-TB treatment such as low education, low income, alcohol abuse, unemployment, and lack of health insurance [8, 9].

MDR-TB treatment, especially the longer regimen is often associated with poor treatment outcome [10]. However, longer regimens are still the main regimen used in MDR-TB endemic
countries in Asia and Africa including Indonesia, while shorter regimens at present are only applied in 20 countries, and only given to patients who do not have contraindications [11].

As studies that evaluate the combination of longer regimens have not been evenly conducted in countries with a high burden of TB and there have not been many studies on the factors that influence the success of MDR-TB using longer treatment regimen [1]. Therefore, in this study, we aimed to identify factors that associated with successful treatment outcome in a high burden MDR-TB setting in Indonesia.

Materials and methods

Design and setting

This was a retrospective cohort study conducted in the Hasan Sadikin General Hospital in Bandung. This hospital is a tertiary referral hospital that provides treatment for drug-resistant TB patients. Data was collected at PMDT (Programmatic Management of Drug-resistant TB) clinic from December 2019 to January 2020. Patients’ information were inputted into e-TB Manager database, which is a system for recording and reporting MDR-TB cases. This study had received approval from the Health Research Ethics Committee of Hasan Sadikin General Hospital number LB.02.01/X.6.5/356/2019. Patient’s data from medical records were de-identified and analyzed anonymously.

Study population

The study population was all MDR-TB patients aged 18 years old or more, who received longer treatment regimens from January 2015 to December 2017. Longer regimen used in our hospital were combination of fluoroquinolone (levofloxacin or moxifloxacin), aminoglycosides injection (kanamycin or capreomycin), ethionamide, cycloserine, and pyrazinamide. Patients were followed up until treatment complete, with minimum duration was 18 months.

Variables

This study analyzed 13 independent variables that might affect outcome of MDR-TB therapy. Age, sex, smoking status, BMI (Body Mass Index), HIV (Human Immunodeficiency Virus), DM (diabetes mellitus), CKD (Chronic Kidney Disease), anemia, history of TB medication, time of sputum conversion, quantity result of Xpert MTB/RIF, AFB (Acid Fast Bacilli) smear, and cavity in baseline thorax x-ray were categorized and presented in proportions and percentages.

The outcome of study was success and unfavorable outcomes. A successful treatment was defined as patient who fulfill recovery criteria or completed treatment. Unfavorable outcomes were defined as a combination of dropout rates, failure of therapy, and death. Success criteria and unfavorable outcomes used in this research were in accordance with WHO criteria [6].

Statistical analysis

Univariate analysis was performed with Chi-square or Fisher’s exact test. Multivariate logistic regression was performed for variables with $p < 0.25$ based on univariate analysis. Stata version 14.2 for Windows was adopted for statistical analysis. Two-tailed $p \leq 0.05$ was considered as statistically significant. Variables that had missing data were excluded from multivariate analysis. Patients who moved to another health facility and treated irregularly were excluded from the study.
Results

Fig 1 showed that there were 537 MDR-TB patients undergoing treatment from January 2015 to December 2017. Five hundred fourteen patients received longer regimens but only 492 patients were fulfilled eligibility criteria and included in this study. Kanamycin-levofloxacin based were the most frequent combination used for MDR-TB patients followed by capreomycin-levofloxacin, capreomycin-moxifloxacin, and kanamycin-moxifloxacin as described by Fig 2. Pyrazinamide, cycloserine, and ethionamide were also added to all combinations.

Overall, the successful treatment rate was 50%. The baseline characteristics were summarized in Table 1. Univariate analysis from Table 2 showed only smoking was not statistically significant between groups with p = 0.415, therefore smoking was not included in multiple logistic regression. Xpert MTB/RIF was not included in multivariate analysis regardless of p<0.05 because of incomplete data.

Multiple logistic regression

Multivariate analysis with logistic regression from 11 factors showed that anemia and DM had no significant effect on the successful treatment (Table 3). Age ≤45 years, male, normal BMI,
Table 1. Characteristics of MDR-TB patients (n = 492).

| Characteristics                      | n (%)          |
|--------------------------------------|----------------|
| Age (years)                          |                |
| ≤ 45                                 | 335 (68)       |
| > 45                                 | 157 (32)       |
| Sex                                  |                |
| Male                                 | 268 (54.5)     |
| Female                               | 224 (45.5)     |
| Current Smoking Status               |                |
| Yes                                  | 271 (55)       |
| No                                   | 221 (45)       |
| BMI (kg/m²)                          |                |
| Underweight                          | 321 (65.3)     |
| Normal                               | 143 (29)       |
| Overweight                           | 16 (3.3)       |
| Obese                                | 12 (2.4)       |
| Anemia                               |                |
| Yes                                  | 252 (51.2)     |
| No                                   | 240 (48.8)     |
| HIV                                  |                |
| Yes                                  | 15 (3)         |
| No                                   | 477 (97)       |
| Diabetes mellitus                    |                |
| Yes                                  | 76 (15.4)      |
| No                                   | 416 (84.6)     |
| CKD                                  |                |
| Yes                                  | 59 (12)        |
| No                                   | 433 (88)       |
| History of TB Medication             |                |
| No previous treatment                | 25 (5)         |
| Relapse                              | 167 (34)       |
| Failed                               | 216 (43.9)     |
| Loss to follow up                    | 84 (17.1)      |

(Continued)
no previous tuberculosis treatment, culture conversion $\leq 2$ months, AFB sputum smear $\leq +1$ were independent factors associated with increased treatment success. Time of sputum conversion in the first two months was the highest factor that increase the chances of success with RR = 2.79 and $p < 0.001$. HIV, CKD, and cavitary lesion were independent risk factors for unfavourable outcome. HIV is a major factor that decreased success rate with 86.1% reduction (RR = 0.14 and $p = 0.017$).

**Discussion**

This was the first retrospective cohort study evaluating multiple factors that influence the success of MDR-TB treatments using longer regimens at the MDR-TB Clinic Hasan Sadikin General Hospital Bandung West Java Indonesia. This study population was 492 patients and analyzed the role of thirteen variables. The results showed that from thirteen variables studied, there were nine factors that influenced the successful treatment rate.

MDR-TB is more common in patients aged $< 45$ years. This results are consistent with MDR-TB epidemiologic study in Indonesia, which showed that 61.6% of MDR-TB patients were in the productive age (18–50 years) [12]. However, patients aged $< 45$ years had success rate 1.19 times higher than older age. Comorbid diseases and atypical symptoms increase the difficulty in diagnosis and management of patients in older age [13]. Physiological and biological changes in elderly also could impair microbial clearance mechanism and reduce cellular immune response [14]. MDR-TB patients over 45 years tend to have failed treatment two times higher and even three times higher in patients aged over 65 years [13]. Older age is associated with lower drug absorption due to reduced intestinal function and motility. Adverse effects and drug interactions are also higher due to reduced liver and kidney function for drug elimination [15]. Retrospective study in Italian referral hospital found that having risk factors of TB (DM, malnutrition, alcohol consumption, and immunosuppressive therapy) and cavities on chest x-ray were predictors of adverse events of TB in elderly [14].
Table 2. Univariate analysis of factors affecting outcome of longer regimen MDR-TB treatment.

| Variables                              | Success | Unfavorable outcomes | p-value* | RR (95% CI) |
|----------------------------------------|---------|----------------------|----------|-------------|
|                                        | n (%)   | n (%)                |          |             |
| Age (years)                            |         |                      |          |             |
| ≤ 45                                   | 178 (53.1) | 157 (46.9)           | 0.042    | 1.23 (0.99–1.51) |
| > 45                                   | 68 (43.3)   | 89 (56.7)            |          |             |
| Sex                                    |         |                      |          |             |
| Male                                   | 153 (57.1) | 115 (42.9)           | 0.001    | 1.37 (1.14–1.66) |
| Female                                 | 93 (41.5)    | 131 (58.5)           |          |             |
| Current Smoking Status                 |         |                      |          |             |
| Yes                                    | 140 (51.7) | 131 (48.3)           | 0.415    | 1.08 (0.90–1.29) |
| No                                     | 106 (48.0) | 115 (52.0)           |          |             |
| BMI (kg/m²)                            |         |                      |          |             |
| Underweight                            | 133 (41.4) | 188 (58.6)           | <0.001   | 1.50 (1.25–1.80) |
| Normal                                 | 89 (62.2)    | 54 (37.8)            |          |             |
| Overweight                             | 14 (87.5)    | 2 (12.5)             | <0.001   | 2.11 (1.68–2.65) |
| Obese                                  | 10 (83.3)    | 2 (16.7)             | <0.001   | 2.01 (1.51–2.67) |
| Anemia                                 |         |                      |          |             |
| Yes                                    | 99 (39.3)    | 153 (60.7)           | <0.001   | 0.64 (0.53–0.77) |
| No                                     | 147 (61.3) | 93 (38.8)            |          |             |
| HIV                                    |         |                      |          |             |
| Yes                                    | 1 (6.7)     | 14 (93.3)            | <0.001   | 0.13 (0.02–0.86) |
| No                                     | 245 (51.4) | 232 (48.6)           |          |             |
| Diabetes mellitus                      |         |                      |          |             |
| Yes                                    | 27 (35.5)    | 49 (64.5)            | 0.006    | 0.67 (0.49–0.93) |
| No                                     | 219 (52.6) | 197 (47.4)           |          |             |
| CKD                                    |         |                      |          |             |
| Yes                                    | 12 (20.3)    | 47 (79.7)            | <0.001   | 0.38 (0.22–0.63) |
| No                                     | 234 (54.0) | 199 (46.0)           |          |             |
| History of TB Medication               |         |                      |          |             |
| No previous treatment                  | 16 (64.0)   | 9 (36.0)             | <0.001   | 3.36 (1.98–5.71) |
| Relapse                                | 127 (76.0)    | 40 (24.0)            | <0.001   | 3.99 (2.55–6.25) |
| Failed                                 | 87 (40.3)    | 129 (59.7)           | 0.002    | 2.11 (1.32–3.38) |
| Loss to follow up                      | 16 (19.0)    | 68 (81.0)            | Reference |          |
| Time of Sputum Conversion              |         |                      |          |             |
| ≤ 2 months                             | 238 (57.6)   | 175 (42.4)           | <0.001   | 5.69 (2.93–11.03) |
| > 2 months                             | 8 (10.1)     | 71 (89.9)            |          |             |
| Xpert MTB/ Rif                          |         |                      |          |             |
| High                                   | 9 (13.0)     | 60 (87.0)            | Reference |          |
| Medium                                 | 44 (43.1)    | 58 (56.9)            | <0.001   | 3.31 (1.73–6.33) |
| Low                                    | 54 (74.0)    | 19 (26.0)            | <0.001   | 5.67 (3.04–10.59) |
| Very low                               | 13 (92.9)    | 1 (7.1)              | <0.001   | 7.12 (3.81–13.32) |
| AFB Smear                              |         |                      |          |             |
| ≤ +1                                   | 161 (89.4)   | 19 (10.6)            | <0.001   | 3.28 (2.72–3.96) |
| > +1                                   | 85 (27.5)     | 227 (72.8)           |          |             |
| Cavity                                 |         |                      |          |             |
| Yes                                    | 48 (22.4)    | 166 (77.6)           | <0.001   | 0.31 (0.24–0.41) |

(Continued)
A study conducted in China in 2018 found 73.65% of MDR-TB patients were male. In addition to the high risk of exposure due to social interactions in men, hormonal factors also play a role in the body’s defense mechanism against TB. Estradiol increases the response of T-helper 1 lymphocytes, interferon gamma (IFN-γ), and tumor necrosis factor-alpha (TNF-α) that play a role in controlling tuberculosis infection. Estradiol also plays a role in the activation of macrophages, while testosterone plays a role in the activation and motility of neutrophils. The role of neutrophils in the pathology of tuberculosis is still less investigated [7, 13, 16, 17]. Our study found that male were 1.24 times to have successful treatment compared to women with p = 0.005. Studies in Africa, Bangladesh, and Syria found that women were more difficult to reach health services because of cultural barriers and low levels of education [18]. However, this study did not evaluate further regarding education, culture, and socioeconomics role.

TB infection increases the anabolic process, accompanied by reduced appetite and increased nutrient malabsorption. YY peptide hormone secreted by the distal small intestine and large intestine will increase in the presence of TB infection. This hormone plays a role in regulating appetite and absorption of nutrients [19]. This study found that MDR-TB patients with normal BMI have a 1.21 times higher chance of successful treatment compared to underweight. Studies in India showed that BMI <18 kg/m² increases the risk failed treatment by 1.64 times (95% CI 1.28–2.11; p <0.001) [7]. Malnutrition interferes with cell-mediated immunity and increases the risk of drug-induced liver injury (DILI). Malnutrition also interferes with the pharmacokinetics of drugs, including anti-TB drugs, thereby reducing drug levels in the blood and decreasing the therapeutic effect of the drug [20].

In this study, HIV is the main factor that reduces the chance of successful therapy (86.1%) with p = 0.017. Not only for MDR-TB patients, HIV positive is also associated with therapy failure among drug-sensitive TB [21]. Cell-mediated immunity, specifically CD4 T lymphocytes, plays an important role in controlling TB infection. HIV patients with low CD4 T lymphocyte levels will increase the risk of severe TB infection and treatment difficulties [22]. In a systematic literature review and meta-analysis study in Sub-Saharan Africa, it was found that the mortality rate of MDR-TB with HIV up to 18.1% [23]. MDR-TB patients with HIV have many drugs to take so that drug interactions are higher. This also causes decreasing medication adherence and greater side effects [24]. Microbiological confirmation is also difficult to obtain in HIV patients which causes delays in handling MDR-TB [22, 25].

CKD is other comorbid that can reduce successful treatment rate (RR 0.62; p = 0.024). Patients with CKD have a weak immune system due to chronic inflammatory conditions [26]. Studies conducted in Taiwan found that CKD can increase severe drug reactions and mortality MDR-TB patients by 3.65 times (95% CI = 1.71–7.76). MDR-TB patients with CKD experience side effects more frequent and more progressive decline in kidney function [26, 27].

Primary MDR-TB patients have a higher chance of successful treatment 2.20 times compared to loss to follow-up. A study conducted in Malaysia found that TB treatment history was the strongest risk factor for determining treatment outcomes (adjusted OR 4.87; 95% CI: 2.84–8.38; p = 0.001). A history of TB treatment will increase the risk for large amounts of drug

| Variables | Success n (%) | Unfavorable outcomes n (%) | p-value | RR (95% CI) |
|-----------|--------------|----------------------------|---------|-------------|
| No        | 198 (71.2)   | 80 (28.8)                  |         |             |

*p<0.05 considered statistically significant. Univariate analysis was performed using Chi-Square, BMI: Body Mass Index; HIV: Human Immunodeficiency Virus; CKD: Chronic Kidney Disease; TB: Tuberculosis; AFB: Acid-Fast Bacilli; RR: Relative Risk; CI: Confidence Interval.

https://doi.org/10.1371/journal.pone.0246284.t002
Special attention must be given for factors that underlie the incidence of loss to follow-up, so it does not reoccur in subsequent treatments [28].

Time of sputum conversion ≤2 months is a major factor that increase the chances of success based on multivariate analysis (RR 2.79; 95% CI 1.61–4.84; p-value = <0.001). Sputum culture has an important role in evaluating the treatment response [5, 6]. A study conducted in

### Table 3. Multivariate analysis of factors affecting outcome of longer regimen MDR-TB treatment.

| Variables                              | Initial Model | Final Model |
|----------------------------------------|---------------|-------------|
|                                        | Crude RR (95% CI) | p-value | Adjusted RR (95% CI) | p-value |
| Age (years)                            |               |            |                     |         |
| ≤ 45                                   | 1.18 (1.01–1.38) | 0.034      | 1.19 (1.02–1.38)    | 0.028   |
| > 45                                   | Reference     |            | Reference           |         |
| Sex                                    |               |            |                     |         |
| Male                                   | 1.23 (1.07–1.43) | 0.006      | 1.24 (1.06–1.44)    | 0.005   |
| Female                                 | Reference     |            | Reference           |         |
| BMI (kg/m²)                            |               |            |                     |         |
| Underweight                            | Reference     |            | Reference           |         |
| Normal                                 | 1.18 (1.02–1.36) | 0.026      | 1.21 (1.05–1.39)    | 0.007   |
| Overweight                             | 1.52 (1.13–2.05) | 0.006      | 1.54 (1.15–2.07)    | 0.004   |
| Obese                                  | 1.43 (1.01–2.02) | 0.043      | 1.45 (1.02–2.05)    | 0.039   |
| Anemia                                 |               |            |                     |         |
| Yes                                    | 0.99 (0.77–1.03) | 0.109      |                     |         |
| No                                     | Reference     |            | Reference           |         |
| HIV                                    |               |            |                     |         |
| Yes                                    | 0.15 (0.03–0.75) | 0.021      | 0.14 (0.03–0.70)    | 0.017   |
| No                                     | Reference     |            | Reference           |         |
| Diabetes mellitus                      |               |            |                     |         |
| Yes                                    | 0.96 (0.78–1.18) | 0.695      |                     |         |
| No                                     | Reference     |            | Reference           |         |
| CKD                                    |               |            |                     |         |
| Yes                                    | 0.63 (0.41–0.96) | 0.031      | 0.62 (0.41–0.94)    | 0.024   |
| No                                     | Reference     |            | Reference           |         |
| History of TB Medication               |               |            |                     |         |
| No previous treatment                  | 2.20 (1.40–3.48) | 0.001      | 2.20 (1.40–3.47)    | 0.001   |
| Relapse                                | 2.20 (1.50–3.23) | <0.001     | 2.20 (1.50–3.22)    | <0.001  |
| Failed                                 | 1.75 (1.19–2.56) | 0.004      | 1.77 (1.21–2.58)    | 0.003   |
| Loss to follow up                      | Reference     |            | Reference           |         |
| Time of Sputum Conversion              |               |            |                     |         |
| ≤ 2 months                             | 2.77 (1.60–4.81) | <0.001     | 2.79 (1.61–4.84)    | <0.001  |
| > 2 months                             | Reference     |            | Reference           |         |
| AFB Smear                              |               |            |                     |         |
| ≤ +1                                   | 1.96 (1.62–2.37) | <0.001     | 1.99 (1.64–2.40)    | <0.001  |
| > +1                                   | Reference     |            | Reference           |         |
| Cavity                                 |               |            |                     |         |
| Yes                                    | 0.60 (0.48–0.76) | <0.001     | 0.59 (0.47–0.75)    | <0.001  |
| No                                     | Reference     |            | Reference           |         |

Multivariate analysis using logistic regression. BMI: Body Mass Index; HIV: Human Immunodeficiency Virus; CKD: Chronic Kidney Disease; TB: Tuberculosis; AFB: Acid-Fast Bacilli; RR: Relative Risk; CI: Confidence Interval.

https://doi.org/10.1371/journal.pone.0246284.t003
China also showed that time of sputum conversion in the first two months increased the successful treatment rate by 2.88 times with 95% CI: 1.11–7.45 [29]. Longer sputum conversion describes more drugs to which *M. tuberculosis* resistant. The effectiveness of second-line anti-TB drugs in MDR-TB patients is best evaluated in the first eight weeks of administration [30].

AFB smear ≤+1 increased the chance of successful treatment by 1.99 times (95% CI: 1.64–2.40, p = 0.001). This is consistent with a study in China that found MDR-TB patients with AFB smear >+1 had a lower tendency for culture conversion (Hazard ratio = 0.61; 95% CI: 0.41–0.91; p = 0.001). This is due to the greater bacterial load at a higher degree of positivity [5]. Fredejas, et al. (2018) found that semi-quantitative Xpert MTB/RIF assay equivalent to AFB smear, though this assay remains underutilised in many countries, including Indonesia. The degree of smear positivity is operator dependent so it has varying sensitivity. Therefore, WHO recommends Xpert MTB/RIF as the first test for TB diagnosis but does not replace the role of AFB smear [31]. AFB smear proved to play an independent risk factor in determining the successful treatment of MDR-TB.

High bacterial load is also described by the presence of cavitary lesions based on chest radiograph. Cavitary lesions decrease the chance of successful therapy by 40.5% (RR: 0.59; 95% CI: 0.47–0.75; p-value = <0.001). A study in China found that cavity increased the risk of poor treatment outcomes by 1.42 times (95% CI: 1.18–1.73; p-value = <0.001) [13]. Cavitary lesions are heterogeneous with a very high number of TB bacteria. Cavity, especially bilateral cavity, increases the relapse rate, resistance, and failure of therapy for MDR-TB patients due to the difficulty of drug penetration into cavity lesions [32].

The TB and DM interactions potentially cause adverse impact by increasing each other’s complications, making diagnosis and treatment more difficult, worsening disease course and outcome [33]. In our study, we found 15% of MDR-TB patients has DM at baseline before treatment initiation. The DM prevalence among MDR-TB patients is much higher compared to those with drug-sensitive TB [21, 34]. DM disrupts cellular immunity, chemotactic effect and phagocytosis of alveolar macrophage, interferon gamma, and also causes pulmonary microangiopathy and micronutrient deficiency. DM patients also have a high risk for impaired renal function and DILI [35]. Therefore, active screening of DM in patients with TB is highly recommended [33].

A study conducted in Korea found that successful treatment were lower in DM type 2 compared to without DM (36 vs. 47.2%, p = 0.002) [36]. Interestingly, another study stated that there was no difference between MDR-TB patients with DM and without DM with p = 0.054 [37].

The interaction of anti-TB drugs and anti-diabetes drugs is one of the factors that influence the success of therapy. Glycemic control is an important factor that can improve the therapeutic response and severity of MDR-TB patients with comorbid DM, but this study did not investigate role glycemic control in patients. This study also did not distinguish between the length of diagnosis of DM, which proved to have a role in TB severity [36, 38, 39].

Anemia is also a proven as a factor influence success in bivariate analysis (RR: 0.64; 95% CI: 0.53–0.78; p-value = <0.001), but is not an independent risk factor. The mechanism underlying anemia causes poor MDR-TB treatment outcomes are not well known. Iron deficiency anemia causes interference with T-cell-mediated immunity [40]. Irbah, et al found that anemia affect the time of sputum conversion, but the type and severity of anemia did not affect the delay in conversion [41].

Smoking status is the only risk factor that has not been proven to influence the success of MDR-TB treatment. Cigarette smoke affects the activity of macrophages and lymphocytes in the lung [42]. De-Boer, et al. (2014) states that changes in smoker immunity are influenced by the amount and duration of smoking. Smoking more than 20 cigarettes a day affects the
success of MDR-TB treatments [43]. Our study did not evaluate the number of cigarettes in a day, the duration of smoking, the type of cigarette, and the history of smoking cessation during treatment.

Some limitation should be noted. This study used data from medical record so it could not evaluate other socioeconomic demographic variables and did not specifically analyze onset and severity of comorbid disease. Anti-TB drugs adverse effect was also not recorded.

Conclusions

Male, age ≤45 years, normal BMI, sputum culture conversion ≤2 months, AFB smear ≤+1 and no previous TB treatment were factors independently increase treatment success, with the major factor was sputum culture conversion ≤ 2 months. On the other hand HIV, CKD, and presence of cavitary lesions were risk factors of unfavourable outcome. These factors should always be considered in managing TB-MDR/RR patients with longer regimen.

Supporting information

S1 File. Data MDR-TB outcome. (ODS)

Acknowledgments

AYS and CP conceived and designed the study. CP acquired the data. AYS, PS, CP, BWL contributed to the writing and revising the manuscript.

Author Contributions

Data curation: Bony Wiem Lestari.

Formal analysis: Bony Wiem Lestari.

Methodology: Arto Yuwono Soeroto, Chica Pratiwi, Prayudi Santoso.

Software: Bony Wiem Lestari.

Writing – original draft: Arto Yuwono Soeroto, Chica Pratiwi.

Writing – review & editing: Arto Yuwono Soeroto, Chica Pratiwi, Prayudi Santoso, Bony Wiem Lestari.

References

1. World Health Organization. TB disease burden. In: Global Tuberculosis Report 2019. 2019:27–72.

2. Heuvelings C, de Vries S, Grobusch M. Tackling TB in low-incidence countries: improving diagnosis and management in vulnerable populations. Int J Infect Dis. 2017; 56:77–80. https://doi.org/10.1016/j.ijid.2016.12.025 PMID: 28062228

3. West Java Provincial Health Office. Multidrug-resistant tuberculosis data analysis in West Java. 2020.

4. Soeroto AY, Lestari BW, Santoso P, Chaidir L, Andriyoko B, Alisjahbana B, et al. Evaluation of Xpert MTB-RIF-guided diagnosis and treatment of rifampicin-resistant tuberculosis in Indonesia: A retrospective cohort study. PLoS One. 2019; 14(2):e0213017. https://doi.org/10.1371/journal.pone.0213017 PMID: 30818352

5. Liu Q, Lu P, Martinez L, Yang H, Lu W, Ding X, et al. Factors affecting time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis in China. BMC Infect Dis. 2018; 18(1):114. https://doi.org/10.1186/s12879-018-3021-0 PMID: 29510866

6. Gadallah MA, Mokhtar A, Rady M, El-Moghazy E, Fawzy M, Kandil SK. Prognostic factors of treatment among patients with multidrug-resistant tuberculosis in Egypt. J Formos Med Assoc. 2016; 115 (11):997–1003. https://doi.org/10.1016/j.jfma.2015.10.002 PMID: 26696497
7. Parmar MM, Sachdeva KS, Dewan PK, Rade K, Nair SA, Pant R, et al. Unacceptable treatment outcomes and associated factors among India’s initial cohorts of multidrug-resistant tuberculosis (MDR-TB) patients under the revised national TB control programme (2007–2011): Evidence leading to policy enhancement. PLoS One. 2018; 13(4):e0193903. https://doi.org/10.1371/journal.pone.0193903 PMID: 29641576

8. Di Gennaro F, Pizzol D, Cebola B, Stubbs B, Monno L, Saracino A, et al. Social determinants of therapy failure and multi drug resistance among people with tuberculosis: A review. Tuberculosis. 2017; 103:44–51. https://doi.org/10.1016/j.tube.2017.01.002 PMID: 28237033

9. Pradipita IS, Forsman LD, Bruchfeld J, Hak E, Alffenaaar J-W. Risk factors of multidrug-resistant tuberculosis: A global systematic review and meta-analysis. J Infect. 2018; 77(6):469–78. https://doi.org/10.1016/j.jinf.2018.10.004 PMID: 30339803

10. Ahmad N, Ahuja SD, Akkerman OW, Alffenaaar J-WC, Anderson LF, Baghaei P, et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis. The Lancet. 2018; 392(10150):821–34. https://doi.org/10.1016/S0140-6736(18)31644-1 PMID: 30215381

11. Falzon D, Schürmann HJ, Harausz E, González-Angulo L, Lienhardt C, Jaramillo E, et al. World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017; 49(3). https://doi.org/10.1183/13993003.02308-2016 PMID: 28331043

12. Kurniawati F, Sulaiman SS, Gillani SW. Study on drug-resistant tuberculosis and tuberculosis treatment on patients with drug resistant tuberculosis in chest clinic outpatient department. Int J Pharm Pharm Sci. 2012; 4(2):73367.

13. Wen Y, Zhang Z, Li X, Xia D, Ma J, Dong Y, et al. Treatment outcomes and factors affecting unsuccessful outcome among new pulmonary smear positive and negative tuberculosis patients in Anqing, China: a retrospective study. BMC Infect Dis. 2018; 18(1):104. https://doi.org/10.1186/s12879-018-3019-7 PMID: 29506480

14. Di Gennaro F, Vitozzi P, Gualano G, Musso M, Mosti S, Mencarini P, et al. Active Pulmonary Tuberculosis in Elderly Patients: A 2016–2019 Retrospective Analysis from an Italian Referral Hospital. Antibiotics. 2020; 9(8):489. https://doi.org/10.3390/antibiotics9080489 PMID: 32794552

15. Velayutham BRV, Nair D, Chandrasekaran V, Raman B, Sekar G, Watson B, et al. Profile and response to anti-tuberculosis treatment among elderly tuberculosis patients treated under the TB Control programme in South India. PLoS One. 2014; 9(3):e88045. https://doi.org/10.1371/journal.pone.0088045 PMID: 24618888

16. Nhamoyebonde S, Leslie A. Biological differences between the sexes and susceptibility to tuberculosis. The Journal of infectious diseases. 2014; 209(suppl_3):S100–S6. https://doi.org/10.1093/infdis/jiu147 PMID: 24966189

17. Elliott E, Draper H, Baitiwi P, Claassens M. Factors affecting treatment outcomes in drug-resistant tuberculosis cases in the Northern Cape, South Africa. Public Health Action. 2014; 4(3):201–3. https://doi.org/10.5585/pha.14.0029 PMID: 26400811

18. Widyasriini ER, Probandari AN, Reviono R. Factors Affecting the Success of Multi Drug Resistance (MDR-TB) Tuberculosis Treatment in Residential Surakarta. Journal of Epidemiology and Public Health. 2017; 2(1):45–57. https://doi.org/10.26911/jepublichealth.2017.02.01.05

19. Chang SW, Pan WS, Beltran DL, Baldelomar LO, Solano MA, Tuero I, et al. Gut hormones, appetite suppression and cachexia in patients with pulmonary TB. PLoS One. 2013; 8(1):e54564. https://doi.org/10.1371/journal.pone.0054564 PMID: 23358528

20. Ministry of Health and Family Welfare-Government of India. Guidance document: Nutritional care and support for patients with Tuberculosis in India. 2017:1–101.

21. Pizzol D, Veronesi N, Marotta C, Di Gennaro F, Moiaine J, Cebola B, et al. Predictors of therapy failure in newly diagnosed pulmonary tuberculosis cases in Beira, Mozambique. BMC Res Notes. 2018; 11(1):1–6. https://doi.org/10.1186/s13104-017-3088-5 PMID: 29291749

22. Isaakidis P, Casas E, Das M, Tseretopoulou X, Ntzani E, Ford N. Treatment outcomes for HIV and MDR-TB co-infected adults and children: systematic review and meta-analysis. The International Journal of Tuberculosis and Lung Disease. 2015; 19(8):969–78. https://doi.org/10.5588/ijtld.15.0123 PMID: 26162364

23. Van Hout MC, Hope V. Treatment outcomes and antiretroviral uptake in multidrug-resistant tuberculosis and HIV co-infected patients in Sub-Saharan Africa: a systematic review and meta-analysis. BMC Infect Dis. 2019; 19(1):723. https://doi.org/10.1186/s12879-019-4317-4 PMID: 31420021

24. Azeez A, Ndege J, Mutambayi R. Associated factors with unsuccessful tuberculosis treatment outcomes among tuberculosis/HIV coinfected patients with drug-resistant tuberculosis. International Journal of Mycobacteriology. 2018; 7(4):347. https://doi.org/10.4103/ijmy.ijmy_140.18 PMID: 30531033
25. Magis-Escarra C, Günther G, Lange C, Alexandru S, Altrichter N, Avsar K, et al. Treatment outcomes of MDR-TB and HIV co-infection in Europe. Eur Respir J. 2017; 49(6). https://doi.org/10.1183/13993003.02363-2016 PMID: 2859434

26. Reis-Santos B, Gomes T, Horta BL, Maciel ELN. The outcome of tuberculosis treatment in subjects with chronic kidney disease in Brazil: a multinominal analysis. Jornal Brasileiro de Pneumologia. 2013; 39(5):585–94. https://doi.org/10.1590/S1806-37132013000500009 PMID: 24310632

27. Yu M-C, Chiang C-Y, Lee J-J, Chien S-T, Lin C-J, Lee S-W, et al. Treatment outcomes of multidrug-resistant tuberculosis in Taiwan: tackling loss to follow-up. Clin Infect Dis. 2018; 67(2):202–10. https://doi.org/10.1093/cid/ciy066 PMID: 29394358

28. Elmi OS, Hasen H, Abdullah S, Jeab MZM, Ba Z, Naing NN. Treatment outcomes of patients with multidrug-resistant tuberculosis (MDR-TB) compared with non-MDR-TB infections in peninsular Malaysia. The Malaysian journal of medical sciences: MJMS. 2016; 23(4):17. https://doi.org/10.21315/mjms2016.23.4.3 PMID: 27660541

29. Lv L, Li T, Xu K, Shi P, He B, Kong W, et al. Sputum bacteriology conversion and treatment outcome of patients with multidrug-resistant tuberculosis. Infection and Drug Resistance. 2018; 11:147. https://doi.org/10.2147/IDR.S153499 PMID: 29416359

30. Kim J, Kwak N, Lee HY, Kim TS, Kim C-K, Han SK, et al. Effect of drug resistance on negative conversion of sputum culture in patients with pulmonary tuberculosis. Int J Infect Dis. 2016; 42:64–8. https://doi.org/10.1016/j.ijid.2015.11.018 PMID: 26692454

31. Fradejas I, Ontañón B, Muñoz-Galleigo I, Ramirez-Vela M, López-Roa P. The value of xpert MTB/RIF-generated CT values for predicting the smear status of patients with pulmonary tuberculosis. Journals of clinical pulmonary and other mycobacterial diseases. 2018; 13:9–12. https://doi.org/10.1016/j.jctube.2018.04.002 PMID: 31720405

32. Kemppner RR, Barth AB, Vashakidze S, Nikolaishvili K, Sabulua I, Tukvadze N, et al. Cavitary penetration of levofloxacin among patients with multidrug-resistant tuberculosis. Antimicrobial Agents Chemotherapy. 2015; 59(6):3149–55. https://doi.org/10.1128/AAC.00579-15 PMID: 25779583

33. Di Gennaro F, Marotta C, Antunes M, Pizzol D. Diabetes in active tuberculosis in low-income countries: to test or to take care? The Lancet Global Health. 2019; 7(6):e707. https://doi.org/10.1016/S2214-109X(19)30173-1 PMID: 31097272

34. Pizzol D, Di Gennaro F, Chthaganal KD, Fabrizio C, Monno L, Putoto G, et al. Prevalence of diabetes mellitus in newly diagnosed pulmonary tuberculosis in Beira, Mozambique. Afr Health Sci. 2017; 17 (3):773–8. https://doi.org/10.4314/ahs.v17i3.20 PMID: 29085405

35. Baghaei P, Marjani M, Javanmard P, Tabarsi P, Masjedi MR. Diabetes mellitus and tuberculosis facts and controversies. Journal of Diabetes & Metabolic Disorders. 2013; 12(1):58. https://doi.org/10.1186/1479-5848-12-58 PMID: 24360398

36. Kang YA, Kim SY, Jo K-W, Kim HJ, Park S-K, Kim T-H, et al. Impact of diabetes on treatment outcomes and long-term survival in multidrug-resistant tuberculosis. Respiration. 2013; 86(6):472–8. https://doi.org/10.1159/000348374 PMID: 23889646

37. Muñoz-Torrico M, Caminero-Luna J, Migliori GB, D’Ambrosio L, Carrillo-Alduenda JL, Villareal-Velarde H, et al. Diabetes is associated with severe adverse events in multidrug-resistant tuberculosis. Archives de Bronconeumologia (English Edition). 2017; 53(6):245–50. https://doi.org/10.1016/j.arbres.2016.10.021 PMID: 28089216

38. Park S, Shin J, Kim J, Park I, Choi B, Choi J, et al. The effect of diabetic control status on the clinical features of pulmonary tuberculosis. Eur J Clin Microbiol Infect Dis. 2012; 31(7):1305–10. https://doi.org/10.1007/s10096-011-1443-3 PMID: 23204259

39. Ugarte-Gil C, Alisjahbana B, Ronacher K, Riza AL, Koesoemadinata RC, Malherbe ST, et al. Diabetes mellitus among pulmonary tuberculosis patients from 4 tuberculosis-endemic countries: the TANDEM study. Clin Infect Dis. 2020; 70(5):780–8. https://doi.org/10.1093/cid/ciz284 PMID: 30958236

40. Isanaka S, Mugusi F, Urassa W, Willett WC, Bosch RJ, Villamor E, et al. Iron deficiency and anemia predict mortality in patients with tuberculosis. The Journal of nutrition. 2012; 142(2):350–7. https://doi.org/10.3945/jn.111.144287 PMID: 23002363

41. Irbah S, Pratiwi A, Vidiast F, Handayani D. The impact of anemia in prolonged culture conversion among MDR-TB patients in persahabatan hospital Indonesia. Int J Infect Dis. 2019; 79:91. https://doi.org/10.1016/j.ijid.2015.11.018 PMID: 26692454

42. Pazarlı P, Duman DY, Moçin ÖY, Karagöz T. The Effect of Smoking on Treatment Outcome of Multidrug-Resistant Tuberculosis. Turkish Thoracic Journal. 2013; 14:93–7. https://doi.org/10.5152/ttd.2013.20

43. de Boer RN, e Souza JBDO, Cobelens F, de Paula Ramalho D, Miranda PPC, de Logo K, et al. Delayed culture conversion due to cigarette smoking in active pulmonary tuberculosis patients. Tuberculosis. 2014; 94(1):87–91. https://doi.org/10.1016/j.tube.2013.10.005 PMID: 24321739